Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.00.
Several research firms have weighed in on ADPT. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. increased their price target on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd.
Read Our Latest Research Report on ADPT
Institutional Trading of Adaptive Biotechnologies
Adaptive Biotechnologies Stock Up 0.9 %
Shares of Adaptive Biotechnologies stock opened at $4.68 on Wednesday. Adaptive Biotechnologies has a twelve month low of $2.28 and a twelve month high of $5.80. The company has a market cap of $689.68 million, a price-to-earnings ratio of -3.14 and a beta of 1.44. The company’s 50 day moving average is $4.69 and its 200 day moving average is $3.89.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. Adaptive Biotechnologies had a negative net margin of 126.49% and a negative return on equity of 60.99%. The business had revenue of $43.19 million for the quarter, compared to the consensus estimate of $38.63 million. During the same period last year, the firm earned ($0.33) earnings per share. The company’s quarterly revenue was down 11.7% on a year-over-year basis. Sell-side analysts expect that Adaptive Biotechnologies will post -1.19 EPS for the current fiscal year.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- How to Calculate Options Profits
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is a Secondary Public Offering? What Investors Need to Know
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is the NASDAQ Stock Exchange?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.